-
UPDATED COST-EFFECTIVENESS ANALYSIS OF POLATUZUMAB VEDOTIN COMBINED WITH CHEMOIMMUNOTHERAPY FOR UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN CHINA: EVIDENCE FROM LONG-TERM FOLLOW-UP OF THE POLARIX ASIAN SUBGROUP
Mar 18, 2026, 21:38 PM -
SOURCES OF BIAS IN PATIENT-REPORTED OUTCOME (PRO) DATA COLLECTION: EVIDENCE GAPS IN THEIR IMPACT ON DATA QUALITY
Mar 18, 2026, 21:38 PM -
PATIENT ATTITUDES TO SHARED DECISION-MAKING AND INNOVATIONS IN MUSCLE INVASIVE BLADDER CANCER: A MULTI-COUNTRY FOCUS GROUP
Mar 18, 2026, 21:38 PM -
COST-UTILITY ANALYSIS OF SACITUZUMAB TIRUMOTECAN (SAC-TMT) IN PREVIOUSLY TREATED EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS: A CHINESE HEALTHCARE SYSTEM PERSPECTIVE
Mar 18, 2026, 21:38 PM -
PRIORITIZING AND COSTING RMNCH INNOVATIONS FOR SCALABLE IMPACT: A COMBINED MCDA AND COSTING APPROACH FROM ETHIOPIA
Mar 18, 2026, 21:38 PM -
HOW IMPROVING SCHOOL-AGED CHILDREN’S HEALTH CAN SIMULTANEOUSLY REDUCE INEQUALITY IN BOTH HEALTH AND WEALTH
Mar 18, 2026, 21:38 PM -
AUTOMATING MODEL PARAMETERISATION FOR HEALTH ECONOMIC MODELS: VALIDATION OF A GEN-AI RAG PIPELINE
Mar 18, 2026, 21:38 PM -
CONCEPTUAL COST-EFFECTIVENESS FRAMEWORK FOR GMRX2 (TELMISARTAN/AMLODIPINE/INDAPAMIDE) AS EARLY COMBINATION THERAPY FOR US ADULTS WITH HYPERTENSION WITHOUT MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, USED EITHER AT INITIATION OR AS A STEP-UP FROM...
Mar 18, 2026, 21:38 PM -
DELAYED DIAGNOSIS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) AMONG PATIENTS TREATED WITH TAFAMIDIS
Mar 18, 2026, 21:38 PM -
HEALTH-ECONOMIC VALUE OF A NOVEL ANASTOMOSIS PROTECTION DEVICE AFTER COLORECTAL RESECTION: AN ANALYSIS BASED ON THE SAFE-2025 STUDY AND U.S. CLAIMS DATA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF INTEGRATING BREAST CANCER SCREENING INTO AN EXISTING CERVICAL CANCER SCREENING PROGRAM IN CAMEROON
Mar 18, 2026, 21:38 PM -
REAL-WORLD EFFECTIVENESS OF DUPILUMAB IN REDUCING ORAL AND INHALED CORTICOSTEROID USE AMONG US PATIENTS WITH ASTHMA: ANALYSIS FROM THE HEALTHCARE INTEGRATED RESEARCH DATABASE
Mar 18, 2026, 21:38 PM -
MODELLING ASSOCIATIONS BETWEEN EXTREME POVERTY TRAJECTORIES AND POPULATION GROWTH FOR HEALTH SYSTEMS PLANNING
Mar 18, 2026, 21:38 PM -
ESTIMATING STATE- AND COUNTY-LEVEL CHRONIC DISEASE AND RISK FACTOR PREVALENCE: VALIDATING A SYNTHETIC POPULATION APPROACH USING NATIONALLY REPRESENTATIVE SURVEY DATA
Mar 18, 2026, 21:38 PM -
BREAKING THE BOTTLENECK: A NOVEL HUMAN+AI PROCESS FOR GENERATING FULLY-ANNOTATED, FOUNDATIONAL-DRAFT PRO MANUSCRIPTS FROM SOURCE MATERIALS IN UNDER 48 HOURS
Mar 18, 2026, 21:38 PM -
ECONOMIC EVALUATION OF BLINATUMOMAB PLUS CHEMOTHERAPY IN CHILDREN WITH STANDARD RISK B CELL ACUTE LYMPHOBLASTIC LEUKEMIA AT AVERAGE RISK OF RELAPSE IN HONG KONG
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BENEFIT OF A PRE-FILLED SYRINGE AS A ROUTE OF ADMINISTRATION: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
ECONOMIC IMPACT OF EARLY DIAGNOSIS AND TREATMENT FOR INBORN ERRORS OF IMMUNITY WITH A FOCUS ON COMMON VARIABLE IMMUNODEFICIENCY (CVID) IN SPAIN: A COST-EFFECTIVENESS PERSPECTIVE
Mar 18, 2026, 21:38 PM -
PREDICTORS OF ANTIDEPRESSANT SWITCH AND ASSOCIATED COSTS IN MAJOR DEPRESSIVE DISORDER: A PROSPECTIVE STUDY FROM A TERTIARY-CARE HOSPITAL IN INDIA
Mar 18, 2026, 21:38 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Mar 18, 2026, 21:38 PM
